<DOC>
	<DOCNO>NCT00440206</DOCNO>
	<brief_summary>Purpose identify whether immune markerscan predict success salvage anti-retroviral therapy .</brief_summary>
	<brief_title>Multicenter Trial Immunologic Markers Predict Long Term Virologic Outcomes</brief_title>
	<detailed_description>Over last several year two marker disease utilized determine antiretroviral therapy successful , one CD4 cell count ( reflect immunocompetence infected individual ) HIV viral load ( blood test use determine amount HIV infect individual ) . However patient fail first line therapythe likelihood extend resuppressing viral replication subsequent therapy may low 25-50 % . This information may take several month determine new therapy possible continue success . It would preferable additional marker respond therapy first several week therapy , therfore possibly offer patient alternate treatment earlier without potentiatinglong term side effect possible drug resistance .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Patient must HIV infect must &amp; # 8805 ; 18 year old must take combination ARV regimen ( &amp; # 8805 ; 3 drug ) least 3 month . Must experience virologic failure ( viral load &amp; # 8805 ; 50 copies/mL two occasion least 2 week apart ) . must change salvage antiretroviral regimen Patient sign date full infomred consent . Patient follow abnormal laboratory test result previous 3 month : Hemaglobin &amp; lt ; 100 g/L Platelet count &amp; lt ; 20,000 cells/L INR &amp; # 8805 ; 3.5 IU PTT &amp; # 8805 ; 60 IU Patient significant underlying disease ( nonHIV ) might impact immune marker ( eg . advanced liver disease , malignancy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>HIV</keyword>
	<keyword>Immune Markers</keyword>
</DOC>